alafanip has been shown to work in patients who have already exhausted standard therapy.t is, essentially. these patients are candidates for hospice. the first results allowed e, initiate a phase ii study where the alphabet will already be studied in previously untreated patients who have not received. e. medicinal treatment is also gastric cancer, the second indication is ovarian cancer, for which there are also very few drugs and little revolution of data for this tumor. we decided to try to use the alphabet and learn it in patients too, who can no longer receive standard care. the russian company pharm - this is its production and laboratory in the moscow technopark acquired license for alafanib. and already, together with the developers of the drug, it will conduct the second phase of studying research in oncology - this is mainly the study of foreign drugs, and this year, for obvious reasons, there are fewer and fewer of them, and in this regard, we, as a domestic company, are trying to maintain the level . ah and ah, we are taking more and more innovative developmen